Notícias

12 December 2018

Drug buyers' clubs aim to tackle HIV prevention 'crisis'

A new generation of drug buyers' clubs like those set up at the height of the AIDS epidemic is seeking to combat a "crisis" in preventing new HIV infections by providing access to cheap generics of a breakthrough prophylactic.
12 December 2018

A PrEP makeover: designing real-world HIV prevention for women

Stigma can prevent women from accessing PrEP to prevent HIV infection. The right design can make it feel like a self-care product than a medical treatment.
10 December 2018

Stop blaming PrEP for the rise in STIs – the picture is more complex than that

When MSM seek out PrEP, it is a decision that should be supported. To castigate them is to increase stigma and discourage their engagement with health services. We must encourage PrEP use, accept that condom use may fall as a result, design supportive care and be happy knowing that every averted HIV infection is a life-altering moment.
3 December 2018

South Africa sleeping on the most successful HIV weapons

Oral pre-exposure prophylaxis (PrEP), taken as a once-daily pill, has been hailed the world over as one of the major HIV prevention interventions in the fight against AIDS. Yet, apart form sex workers, very few South Africans are using PrEP or even know it exists.
1 December 2018

Lloyd Russell-Moyle: Why I decided to go public about being HIV positive

Labour MP Lloyd Russell-Moyle revealed he was HIV positive in a speech to the House of Commons. This is what he said.
1 December 2018

WHO commends Viet Nam for increasing access to PrEP for HIV prevention and sexual health

On the eve of World AIDS Day 2018, the Government of Viet Nam launched a national rollout of oral pre-exposure prophylaxis (PrEP), in collaboration with its partners. The World Health Organization (WHO) welcomes the decision by Viet Nam’s Ministry of Health to offer PrEP to people at substantial risk of HIV.
30 November 2018

Is the end in sight for HIV? by Matthew Hodson, Executive Director of NAM/aidsmap

Matthew Hodson, Executive Director of NAM/aidsmap, explains the many advances in HIV prevention and asks whether the end of HIV is in sight?
30 November 2018

PrEP: Why I’m part of the trial for the HIV prevention pill

Touted as a way to end HIV within a generation, the HIV prevention pill (PrEP) is being trialled in the UK. We spoke to Zia, an artist, activist and educator, to hear his experiences of taking it.
29 November 2018

The unexpected effects of the HIV prevention pill

PrEP is great at blocking HIV, but as its use grows, so do fears that people will be more sexually reckless and spread other STIs. But researchers are coming to think that the opposite could be true.
29 November 2018

HIV diagnoses fell in the UK in 2017 for the first time among all risk groups, all ethnicities and in all regions, annual report reveals

The 2018 report from Public Health England is entitled Progress towards ending the HIV epidemic in the United Kingdom, and for once the note of optimism in the title is justified.The report describes an epidemic in which new diagnoses fell in gay men, heterosexuals and all other groups; in people born in

No new infections during research on preventive HIV pill in Belgium

According to the latest figures from Sciensano, 890 new diagnoses were made in Belgium last year, mainly in gay men and people from sub-Saharan Africa. This is a decrease of 27% compared to the peak of 2012.
26 November 2018

High levels of unmet PrEP needs among transgender women in Brazil

A study recently published in The Journal of Acquired Immune Deficiency Syndromes indicates that transgender (trans) women in Brazil had low levels of pre-exposure prophylaxis (PrEP) awareness. This was combined with significant proportions being willing to use PrEP as a prevention tool and being eligible for PrEP.Another recent qualitative study published in Culture, Health and Sexuality
15 November 2018

Removable PrEP implant produces high drug levels in rabbits; further studies planned

A small removable plastic implant resembling a tiny piece of dry spaghetti is capable of delivering sustained levels of the drug tenofovir, researchers told last month’s HIV Research for Prevention conference (HIVR4P 2018) in Madrid.The drug delivery capability of the implants was tested on rabbits and will now advance into tests on dogs
13 November 2018

PROUD qualitative findings: PrEP’s impact on sexual behaviour

Qualitative data from the PROUD study revealed that pre-exposure prophylaxis (PrEP) is an important added prevention tool to strategies already in place for men in England having frequent condomless sex, according to a recent article in AIDS and Behavior. While approximately half of the participants indicated that they had made changes to other risk reduction strategies
9 November 2018

Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than cisgender men

A study presented at last month’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure prophylaxis (PrEP) have levels of the PrEP drugs tenofovir and emtricitabine in their blood that are about 25% lower than those in cisgender men, and levels in
7 November 2018

PrEP sorting: HIV-negative gay men prefer sexual partners who are using PrEP

PrEP status is a significant factor for HIV-negative men who have sex with men (MSM) when selecting sexual partners, but not when choosing friends or romantic partners for dating, according to an American study published in AIDS Care. The authors investigated whether use of pre-exposure prophylaxis (PrEP) influenced partner selection on an online dating
2 November 2018

How safe is PrEP? Meta-analysis finds no increased risk of serious side-effects

A meta-analysis of randomised controlled trials of tenofovir or tenofovir/emtricitabine as pre-exposure prophylaxis (PrEP) has found no increase in the risk of serious adverse health events over placebo. In particular, there was no increase in bone fractures or significant kidney dysfunction, although there was more mild kidney dysfunction (grades 1
31 October 2018

Going local – prevention conference hears about rings, douches, and soluble suppositories

Last week’s HIV Research for Prevention conference (HIVR4P 2018) in Madrid heard a lot about oral pre-exposure prophylaxis (PrEP): not only its efficacy but also that poor retention and adherence could severely limit its impact in some populations.There is therefore interest in injections and implants, although the lengthy persistence of drug
31 October 2018

Beyond Truvada – what is the future of PrEP?

Oral pre-exposure prophylaxis (PrEP) based on tenofovir disoproxil fumarate/emtricitabine (Truvada) has set a high bar for prevention effectiveness, but a range of alternative PrEP products are in development, Raphael Landovitz of the University of California told the HIV Research for Prevention conference (HIVR4P 2018) in Madrid last week. They variously promise less frequent dosing,
30 October 2018

Substantial gaps in PrEP care continuum for trans women in San Francisco

Only a third of trans women in San Francisco have talked to a healthcare provider about pre-exposure prophylaxis (PrEP) and just 12% are taking it, Albert Liu of the San Francisco Department of Public Health told the HIV Research for Prevention conference (HIVR4P 2018) in Madrid last week. Gay and other men who